SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
（深圳市海普瑞藥業集團股份有限公司）

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 9989)

PROXY FORM

FOR THE 2023 FIRST EXTRAORDINARY GENERAL MEETING TO BE HELD ON FRIDAY, DECEMBER 15, 2023

I/W *(Note 1)* _____,

(Note 2) _____ b

d d ( ) *(Note 3)* _____ H a RMB1.00 ac

a ca a **Shenzhen Hepalink Pharmaceutical Group Co., Ltd.** (**Company**), b a C a a

(a) _____ (add)

(Notes 4 & 5) _____ ac a /

a d a d / a d / b a a 2023 a d a a (**EGM**) C a

b d a 2:00 . . F da , D c b 15, 2023 a Ba , 2/F, L'H a H , 3031 Na a B a d, Na a D c ,

S , P ' R b c C a (**PRC**) a d a a ad c d a d, ,

a c a a d c (**Notice**) C a da d N b 24, 2023 a d EGM a d

c a c d d a , a a d a c a ca C a c

N c EGM a d , c d ca , a / .

No.	SPECIAL RESOLUTION	FOR *(Note 6)*	AGAINST *(Note 6)*	ABSTAIN *(Note 6)*
1.00	T a d a d a c a c a a d a d a d c d C a			
	ORDINARY RESOLUTION	**FOR** *(Note 6)*	**AGAINST** *(Note 6)*	**ABSTAIN** *(Note 6)*
2.00	T a d c a c d H a C a			
	SPECIAL RESOLUTION	**FOR** *(Note 6)*	**AGAINST** *(Note 6)*	**ABSTAIN** *(Note 6)*
3.00	T a d d ad a ca c d a d d a a c a ba			

Da : _____ S a ( ) *(Note 7)*: _____

Notes:

1. P a a ( ) **BLOCK CAPITALS**.
2. P a add ( ) **BLOCK CAPITALS**.
3. P a b H a C a d a ( ) c a . I b a d, b d d a a H a C a d a ( ).
4. I a a a d H a C a (**H Shares Shareholder**) d a d a d a , a d a a d ad a d b a . A d b a H S a S a d , b a d d .
5. I a a C a a d, a d C a a a d a a d add ( ) d d ac d d. I a d, C a a ac a . **ANY ALTERATION MADE TO THIS PROXY FORM MUST BE INITIALLED BY THE PERSON(S) WHO SIGNS IT.**
6. **IMPORTANT: IF YOU WISH TO VOTE FOR A RESOLUTION, TICK (✓) IN THE RELEVANT BOX BELOW THE BOX MARKED "FOR". IF YOU WISH TO VOTE AGAINST A RESOLUTION, TICK (✓) IN THE RELEVANT BOX BELOW THE BOX MARKED "AGAINST". IF YOU WISH TO ABSTAIN, TICK (✓) IN THE RELEVANT BOX BELOW THE BOX MARKED "ABSTAIN".** I d ca a a a a a a a d a c / d c a / a d, , a d, c d , / a a ab a a / a b (c d a d) c a b d a . T a ab a d b c d ca a a d a .
7. T b d a d da d b H S a S a d / a d a d . I H S a S a d a c a , d a d c a b d c (a) ( ) d a d a . I ca d , a a d b a a d a d a EGM, b .
8. T b a d, , a a , a , d c d, a a c d c c a a , b c d a d d d a H S a a C a , T c I S c L d, a 17/F, Fa Ea F a c C , 16 Ha c R ad, H K a 24 b a ad .
9. C a d c d a d a d a .
10. H S a S a d a d a d c d d a .

PERSONAL INFORMATION COLLECTION STATEMENT

P a Da a a a a a a a da a d d P a Da a (P ac) O d a c , C a 486 La H K (**PDPO**), c c d a d a ' a a d add . Y P a Da a a a ba a d c c a a d P F (R). I a c a , C a a b ab c c . T C a a d c a P a Da a b d a , H S a S a R a a d/ d a c d d ad a , c a d c C a c c R a d c a a a d b a a a a R a d d c a . T P a Da a b a d c d a a b c a R (c d ca a d c d). R acc a d/ c c P a Da a ca b ad acc da c PDPO a d a c d b a d P ac C a c O c T c I S c L d a ab add .